NOC:NYSE
Northrop Grumman Corporation
Data as of 2026-03-10 - not real-time
$747.34
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Northrop Grumman is trading well above its short‑term moving averages, signalling continued bullish momentum. The relative strength index sits in the upper mid‑range, suggesting modest buying pressure but no immediate over‑extension. A bearish MACD crossover has just formed, tempering the upside and hinting at a near‑term correction. Volatility remains elevated, reflecting the sector’s sensitivity to geopolitical events and recent earnings surprise. Fundamentally, the price‑to‑earnings multiple is modestly below the industry average, while the price‑to‑book ratio is high, indicating a premium valuation. The discounted cash flow model places fair value well under the current market price, resulting in a negative upside estimate.
Analysts broadly favor a buy stance, underpinned by a strong backlog of government contracts announced this month. New space‑force and navy contracts deepen long‑term revenue visibility and support the company’s growth narrative. The dividend yield remains modest but the payout ratio is comfortably low, making the dividend sustainable. Leverage is elevated, yet the firm generates robust operating and free cash flow, providing ample coverage for debt obligations. Given the premium price, a cautious hold in the short run combined with a buy outlook for the medium and long horizons is prudent.
Analysts broadly favor a buy stance, underpinned by a strong backlog of government contracts announced this month. New space‑force and navy contracts deepen long‑term revenue visibility and support the company’s growth narrative. The dividend yield remains modest but the payout ratio is comfortably low, making the dividend sustainable. Leverage is elevated, yet the firm generates robust operating and free cash flow, providing ample coverage for debt obligations. Given the premium price, a cautious hold in the short run combined with a buy outlook for the medium and long horizons is prudent.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 7/10
Key Factors
- bearish MACD crossover
- elevated volatility
- premium market price
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- strong contract backlog
- analyst buy consensus
- sustainable dividend
Long Term
> 3 yearsbuy
Conviction: 9/10
Key Factors
- defense spending tailwinds
- robust free cash flow generation
- low beta and defensive profile
Key Metrics & Analysis
Financial Health
Revenue Growth9.60%
Profit Margin9.97%
P/E Ratio25.7
ROE26.17%
ROA6.64%
Debt/Equity107.26
P/B Ratio6.4
Op. Cash Flow$4.8B
Free Cash Flow$2.9B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI60.1
Support$674.75
Resistance$774.00
MA 20$723.12
MA 50$674.70
MA 200$587.47
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$328.09
Target Price$724.39
Upside/Downside-3.07%
GradeOvervalued
TypeValue
Dividend Yield1.22%
Risk Assessment
Beta0.10
Volatility32.36%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.